ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03386643
Recruitment Status : Recruiting
First Posted : December 29, 2017
Last Update Posted : May 1, 2018
Sponsor:
Information provided by (Responsible Party):
Ana Carolina Fragoso Motta, DDS, PhD, University of Sao Paulo

Brief Summary:
Lichen planus is a chronic inflammatory mucocutaneous disease, which often results in oral manifestations, receiving the name of oral lichen planus (OLP). Its frequency varies from 0,1 to 4% of the general population, with a higher incidence in women, around the 4th and 5th decades of life. Although the pathogenesis of OLP is related to a immune-cellular response, mainly mediated by T lymphocytes, its cause remains unknown. Considering its chronic nature, control of OLP aims to reduce symptoms and improve function, and agents with anti-inflammatory action, especially topical corticosteroids result in some degree of success in most patients, depending on the clinical presentation. However, some cases are resistant to the use of corticosteroids, thus justifying the search for new therapeutic options. The immunomodulation proved to be one of the main functions of probiotic bacteria, and recent studies have shown effect of probiotics on decreasing the expression of inflammatory markers, which enables the study of this therapy as an alternative to the control of OLP. Thus, this project aims to evaluate the effects of therapy with Bifidobacterium animalis subsp. lactis HN019 comparing with clobetasol propionate 0.05% in symptomatic patients with OLP referred for diagnosis and treatment of School of Dentistry of Ribeirão Preto - University of São Paulo (USP). The impact of the topical therapy (probiotic or corticosteroid) on the clinical, histopathological and immunopathological features will be evaluated. This project was previously submitted and approved by the Institutional Review Board of the School of Dentistry of Ribeirão Preto/USP, and all patients must give informed consent to participate in this study.

Condition or disease Intervention/treatment Phase
Oral Lichen Planus Drug: Bifidobacterium animalis subsp. lactis HN019 Drug: Clobetasol propionate 0.05% Phase 2

Detailed Description:
This is a randomized double-blind clinical trial with symptomatic patients presenting OLP, which will be randomly assigned to either topical Bifidobacterium animalis subsp lactis HN019 or clobetasol propionate 0.05%. The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 (experimental group) or 0.05% clobetasol propionate (control group) for mouth washing, twice a day for 4 weeks. Patients will be instructed to maintain normal brushing and not to use or consume another corticosteroid and /or probiotic during the study. Outcomes measures will be symptoms (VAS and Likert-like scale), quality of life (SF-36 form), and clinical changes (erythema, reticulation, erosion/ulcer based on clinical photographs), which will be performed at baseline, 15 days (only VAS, Likert-like scale and photographs) and and at one month of treatment. All patients will undergo biopsies for the diagnosis of OLP, and those who consent will be submitted to an optional biopsy at the end of the topical treatment for histopathological and immunopathological characterization.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Symptomatic patients presenting OLP will be randomly assigned to either topical Bifidobacterium animalis subsp lactis HN019 or clobetasol propionate 0.05%, and they will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 (experimental group) or 0.05% clobetasol propionate (control group) for mouth washing, twice a day for 4 weeks.
Masking: Double (Participant, Investigator)
Masking Description: Both patients and investigators who will assess the outcomes have no knowledge of the interventions assigned to individual participants.
Primary Purpose: Treatment
Official Title: Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus
Actual Study Start Date : November 6, 2017
Actual Primary Completion Date : March 5, 2018
Estimated Study Completion Date : July 6, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Bifidobacterium animalis subsp. lactis

Intervention:

Bifidobacterium animalis subsp. lactis HN019

Drug: Bifidobacterium animalis subsp. lactis HN019
The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
Other Name: Probiotic

Active Comparator: Clobetasol propionate 0.05%

Intervention:

Clobetasol propionate 0.05%

Drug: Clobetasol propionate 0.05%
The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
Other Name: Topical corticosteroid




Primary Outcome Measures :
  1. Change in symptoms intensity measure [ Time Frame: 4 weeks ]
    Self reported symptoms at baseline, 15 and 30 days after therapy through an visual analogue scale (VAS). It consists of a subjective scale scoring the symptoms from 0 to 10 (0 = no symptoms and 10 = as bad as can be).


Secondary Outcome Measures :
  1. Histopathological analysis [ Time Frame: Before (baseline) and one month after intensive topical therapy ]
    Biopsies will be collected at the baseline stage or at the time of the diagnosis of OLP (optional), consisting of a 5mm x 5mm fragment or a 4mm punch of reticular lesions. The second biopsy will be optional, with patient consent, close to the area of the first biopsy for comparative purposes. The histological findings will be determined quantitatively and qualitatively regarding the presence of epithelial hyperplasia, degeneration by liquefaction of the basal cells layer, lymphocytic infiltrate in the subepithelial connective tissue, and apoptotic cells. Photographs will be used at 400x and quantification using the Image J. program.

  2. Immunohistochemical analysis [ Time Frame: After 4 weeks of intensive therapy. ]
    The population of inflammatory cells will be characterized by analysis of oral mucosa samples, with emphasis on the T cell line (CD3, CD4, CD8, CD25, CD103, perforin, granzyme B and Foxp3), B cells (CD20 / CD20), dendritic cells (CD123 and CD303), submucosal dendritic cells (CD209 and factor XIIIa), Langerhans cells (CD1a and CD207), endothelial activity (e-selectin and CD31), mast cells ), macrophages (CD68 and CD163), myeloid dendritic cells (S100 and CD11c), cell proliferation markers (Ki-67, MCM-2, MCM-5, cyclin D1) and extracellular matrix (laminin-5). For immunohistochemical reactions, histological sections of 3μm thickness will be performed, which will be placed on slides coated with organosilane (Sigma-Aldrich, St Louis, MO, USA).

  3. Venous blood collection [ Time Frame: Before (baseline) and after 4 weeks of topical therapy ]
    10 ml of venous blood to evaluate the probiotic systemic effect, by means of the research of pro-inflammatory, anti-inflammatory and regulatory cytokines.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical inclusion

    • Adults ≥ 18 years old, both genres, who consent to participate of the study;
    • Presence of symptomatic reticular lesion and/or white-gray papules. In afro-descendent individuals, reticular lesions may be associated with hyperpigmented lesions;
    • Additional clinical features such as ulcerative, erythematous, plaque and bullous lesions will be accepted in the presence of bilateral and symmetrical reticular lesions.
  • Histopathological inclusion criteria

    • Presence of subepithelial infiltrate predominantly lymphocytic, in band and confined to the subepithelial area.
    • Liquefaction degeneration of the basal cells layer.

Exclusion Criteria:

  • Clinical exclusion criteria

    • Exclusion of contact lichenoid lesions: the pattern of reticular lesion and / or papules should not be present only in areas of physical contact with restorative materials;
    • Exclusion of lichenoid reaction to the drug: difficult to differentiate from OLP, however it is necessary to report all drugs in use by the patient; the comparison between patients on medication, and those who do not use medication is important to establish subgroups of OLP;
    • Exclusion of chronic graft versus host disease (GVHD): differentiation between OLP and GVHD is established in most cases by medical history;
    • Exclusion of immunocompromised patients or patients with systemic diseases of high complexity.
    • Exclusion of patients who have previously used probiotic bacteria in the last 4 weeks prior to the study.
  • Histopathological criteria for exclusion • Presence of epithelial dysplasia, absence of the lymphocytic inflammatory infiltrate band and liquefaction degeneration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03386643


Contacts
Contact: Ana Carolina F Motta, DDS, PhD +55 - 16 - 3315-4067 anacfm@usp.br

Locations
Brazil
School of Dentistry of Ribeirão Preto, University of São Paulo Recruiting
Ribeirão Preto, São Paulo, Brazil, 14040-904
Contact: Ana Carolina F Motta, PhD    +55-16-3315-4067    anacfm@usp.br   
Contact: Átila V Nobre, DDS    +55-16-981076515    atilavnobre@hotmail.com   
Sponsors and Collaborators
University of Sao Paulo
Investigators
Study Chair: Michel Reis Messora, DDS, PhD School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Sergio L. Souza Salvador, DDS, PhD School of Farmacy of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Átila V. Vitor Nobre, DDS School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Cristhiam de J. Hernández Martínez, DDS School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Kleber Tanaka Suzuki, DDS School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Marina C. Gabriel Del Arco School of Farmacy of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Lara Maria A Innocentini, DDS,PhD School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Study Chair: Gilberto A Silva, MS School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.

Publications:
Responsible Party: Ana Carolina Fragoso Motta, DDS, PhD, Teacher of Oral Diagnosis-Department of Stomatology, Public Oral Health and Forensic Dentistry, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT03386643     History of Changes
Other Study ID Numbers: CAAE: 63003716.2.0000.5419
First Posted: December 29, 2017    Key Record Dates
Last Update Posted: May 1, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No plan to make individual participant data available to other researchers.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Ana Carolina Fragoso Motta, DDS, PhD, University of Sao Paulo:
Oral lichen planus
Probiotics
Immunomodulation.

Additional relevant MeSH terms:
Lichen Planus
Lichen Planus, Oral
Lichenoid Eruptions
Skin Diseases, Papulosquamous
Skin Diseases
Mouth Diseases
Stomatognathic Diseases
Clobetasol
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs